TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03382405

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1647
Description: Escalating dose levels

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1443
Description: Escalating dose levels

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline
Study: NCT02851316

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole Body Vibration
Description: Participants will stand in a squatted position on a platform that provides a brief vibratory stimuli.
Study: NCT03601156

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intraarterial chemoembolization

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: intravenous chemotherapy
Study: NCT01113307

Intervention type: BIOLOGICAL
Intervention: Activated allogeneic white blood cells
Description: The CUREXCELL™ dosage form consists of an activated cell suspension that has been isolated, activated and purified from the peripheral blood of healthy allogeneic donors, by hypo-osmotic shock, using the MacroCure custom closed bag system.The cell suspension is superficially injected throughout the wound bed ( 0.1ml per 1 cm2 of wound bed).
Study: NCT01569282

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hepaticojejunostomy and gastroenterostomy
Description: Standard surgical techniques

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stent strategy
Description: Biliary and/or enteral stents on demand
Study: NCT02617498

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: harmonic scalpel
Description: parenchymal liver transection was performed either by harmonic scalpel after demarcation of line of transection by intraoperative US and doppler.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: spray mode diathermy
Description: parenchymal liver transection was performed either by spray mode diathermy after demarcation of line of transection by intraoperative US and doppler.
Study: NCT01983163

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ketogenic diet (2.5 to 4:1)
Description: Minimum ratio (2.5 to4:1) ketogenic diet causing ketosis will be given

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Modified Atkin's diet
Description: 1:1 fixed ketogenic ratio Modified atkins diet will be given
Study: NCT02293239

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole-Body Electromyostimulation (WB-EMS)
Description: WB-EMS training is performed 2x/week for 12 weeks; Stimulation protocol: Frequency of 85 Hz, pulse duration of 0.35 ms, stimulation period of 6 sec, resting period of 4 sec; supervised by certified training instructors/physiotherapists participants perform simple exercises during the stimulation period following a video tutorial
Study: NCT03756597

Intervention type: DEVICE
Intervention: ReCIVA
Description: The ReCIVA breath sampler contains a CO2 and pressure sensor, which allows the operator to monitor the breath sampling procedure and patient comfort. Both the operator and the patient can pause or abort the breath sampling procedure within seconds by removing the mask. The time investment required from patients is approximately 15 minutes for consenting and medical history and 10 minutes per breath collection.

Intervention type: DEVICE
Intervention: ReCIVA
Description: The ReCIVA breath sampler contains a CO2 and pressure sensor, which allows the operator to monitor the breath sampling procedure and patient comfort. Both the operator and the patient can pause or abort the breath sampling procedure within seconds by removing the mask. The time investment required from patients is approximately 15 minutes for consenting and medical history and 10 minutes per breath collection.

Intervention type: DEVICE
Intervention: ReCIVA
Description: The ReCIVA breath sampler contains a CO2 and pressure sensor, which allows the operator to monitor the breath sampling procedure and patient comfort. Both the operator and the patient can pause or abort the breath sampling procedure within seconds by removing the mask. The time investment required from patients is approximately 15 minutes for consenting and medical history and 10 minutes per breath collection.

Intervention type: DEVICE
Intervention: ReCIVA
Description: The ReCIVA breath sampler contains a CO2 and pressure sensor, which allows the operator to monitor the breath sampling procedure and patient comfort. Both the operator and the patient can pause or abort the breath sampling procedure within seconds by removing the mask. The time investment required from patients is approximately 15 minutes for consenting and medical history and 10 minutes per breath collection.

Intervention type: DEVICE
Intervention: ReCIVA
Description: The ReCIVA breath sampler contains a CO2 and pressure sensor, which allows the operator to monitor the breath sampling procedure and patient comfort. Both the operator and the patient can pause or abort the breath sampling procedure within seconds by removing the mask. The time investment required from patients is approximately 15 minutes for consenting and medical history and 10 minutes per breath collection.

Intervention type: DEVICE
Intervention: CASPER
Description: Minimizes contamination of breath samples by external VOCs Removes need for clean air supply line

Intervention type: DEVICE
Intervention: CASPER
Description: Minimizes contamination of breath samples by external VOCs Removes need for clean air supply line

Intervention type: DEVICE
Intervention: CASPER
Description: Minimizes contamination of breath samples by external VOCs Removes need for clean air supply line

Intervention type: DEVICE
Intervention: CASPER
Description: Minimizes contamination of breath samples by external VOCs Removes need for clean air supply line

Intervention type: DEVICE
Intervention: CASPER
Description: Minimizes contamination of breath samples by external VOCs Removes need for clean air supply line
Study: NCT03495297

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ommitence of defibrillation testing
Description: Induction of a ventricular arrhythmia to test proper arrhythmia detection and termination by the implanted device is omitted
Study: NCT02178826

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Appliance
Description: The Placebo Appliance looks exactly like the Rapid maxillary Expander but the expansion screw does not work. When the expansion screw is activated it does not create a palatal expansion.
Study: NCT00999609

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AAV2-hRPE65v2,voretigene neparvovec-rzyl
Description: Subretinal administration of gene therapy vector AAV2-hRPE65v2 (1.5E11 vector genomes per eye) to both eyes via surgical procedures on separate days.
Study: NCT00985660

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nisoldipine Extended-release Tablets, 30 mg
Description: 1 x 30 mg Tablet under fasting conditions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sular® Extended Release Tablets, 30 mg
Description: 1 x 30 mg Tablet under fasting conditions
Study: NCT02974348

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arthemeter-lumefantrine
Description: Randomization codes were computer-generated by an offsite investigator and provided to a study nurse responsible for treatment allocation. All other study personnel were blinded to the treatment assignments, and patients were not informed of their treatment regimen. Participants from Group 1: AL, Group 2 : DHAP, Group3 : ASMQ were also given appointment card for days 1, 2, 3, 7, 14, 21, 28, 35 and 42 for clinical examination and blood smears. Blood was taken on filter paper on each of these visits.
Study: NCT01017783

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary substitution A
Description: Substitution of calorie-dense item with lower calorie choice A

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary Substitution B
Description: Substitution of calorie-dense item with lower calorie option B

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Healthy Choices
Description: Multiple healthy choices presented with self-selection of choices used
Study: NCT03587207

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenABCWY vaccine
Description: Two doses administered intramuscularly in the deltoid region of the non-dominant arm.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: rMenB+OMV NZ (Bexsero) vaccine
Description: Two doses administered 2 months apart intramuscularly in the deltoid region of the non-dominant arm to subjects randomised to the rMenBOMV+ACWY_S Group, rMenBOMV+ACWY_D Group and rMenBOMV Group

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: rMenB+OMV NZ (Bexsero) vaccine
Description: Two doses administered 2 months apart intramuscularly in the deltoid region of the non-dominant arm to subjects randomised to the rMenBOMV+ACWY_S Group, rMenBOMV+ACWY_D Group and rMenBOMV Group

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: rMenB+OMV NZ (Bexsero) vaccine
Description: Two doses administered 2 months apart intramuscularly in the deltoid region of the non-dominant arm to subjects randomised to the rMenBOMV+ACWY_S Group, rMenBOMV+ACWY_D Group and rMenBOMV Group

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MenACWY (Menveo) vaccine
Description: Two doses administered intramuscularly in the deltoid region of the dominant/non-dominant arm to subjects randomised to the rMenBOMV+ACWY_S Group and rMenBOMV+ACWY_D Group and one dose administered intramuscularly in the deltoid region of the dominant/non-dominant arm to subjects randomised to the MenACWY Group

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MenACWY (Menveo) vaccine
Description: Two doses administered intramuscularly in the deltoid region of the dominant/non-dominant arm to subjects randomised to the rMenBOMV+ACWY_S Group and rMenBOMV+ACWY_D Group and one dose administered intramuscularly in the deltoid region of the dominant/non-dominant arm to subjects randomised to the MenACWY Group

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MenACWY (Menveo) vaccine
Description: Two doses administered intramuscularly in the deltoid region of the dominant/non-dominant arm to subjects randomised to the rMenBOMV+ACWY_S Group and rMenBOMV+ACWY_D Group and one dose administered intramuscularly in the deltoid region of the dominant/non-dominant arm to subjects randomised to the MenACWY Group
Study: NCT01131858

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vigantol
Description: Vigantol 4000IU/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00629616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anastrozole
Description: 1 mg/day for either 4 months or 6 months depending on the clinical evaluation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fulvestrant
Description: 500mg at day 1, day 15 and day 29 500mg every 28 days for either 4 months or 6 months depending on the clinical evaluation
Study: NCT02041702

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Non-Diagnostic Cardiac MRI scan
Study: NCT03129919

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Carriere SLX® (Passive self-ligating braces)
Description: Changes in the inclination of the incisors, expansion of the arches at the end of the alignment and leveling phase of the orthodontic treatment

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Empower® (Interactive self-ligating braces)
Description: Changes in the inclination of the incisors, expansion of the arches at the end of the alignment and leveling phase of the orthodontic treatment
Study: NCT02113306

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: t-VNS
Description: The device that will be used is approved for systematic use by those with epilepsy and depression in the European Union. It has been used in studies of acute stimulation with healthy participants with no significant changes in heart rate or breathing (Kraus et al., 2007; Busch et al., 2013).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham stimulation
Description: electrodes will be put upside down
Study: NCT00922532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Nitric Oxide
Description: Inhaled Nitric Oxide will be administered continuously starting at 20ppm through an INOvent delivery system for up to 14 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Nitrogen gas will be administered in the same manor as the experimental drug
Study: NCT01226797

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Take 4 capsules twice daily 12 hours apart with water. Swallow whole.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PF-04136309
Description: Take 4 capsules twice daily 12 hours apart with water. Swallow whole.
Study: NCT04452578

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Procedure: Heart Transplantation
Description: A HCV negative or previously successfully treated recipient who recieves a HCV positive graft will be monitored. Patients who recieve an HCV graft will be treated for HCV according to accepted protocols.
Study: NCT06786611

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: Based on the different manifestations of facet joints under MRI, and with the help of the characteristic manifestations of the gray value curve of facet joints under different subtypes, the curve of facet joints under the same level is fitted, and finally the accurate evaluation of different subtypes of small joints is achieved.
Study: NCT02974348

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artesunate mefloquine
Description: Artequin® is an antimalarial drug presented as infant co-formulation of two separate drugs

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dihydroartemisinin piperaquine
Description: Malacur®. is an antimalarial drug presentad as co-formulation of two separate drugs

Intervention type: DRUG
Group type: OTHER
Intervention: Paracetamol
Description: Paracetamol, is an antipyretic drug, presented as tablets or syrup in infants formulation

Intervention type: DRUG
Group type: OTHER
Intervention: Amoxicillin
Description: Amoxicillin is an antibiotic with no reported activity on plasmodium

Intervention type: DRUG
Group type: OTHER
Intervention: Quinine
Description: quinine sulphate is an antimalaria drug administered as a second line or rescue drug
Study: NCT01005017

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Radiofrequent Lesioning
Description: One group receives PRFLSN after a positive trial block with bupivacaine, the other group receives no extra treatment besides optimal medical treatment.
Study: NCT03563716

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atezolizumab
Description: Atezolizumab at a fixed dose of 1200 mg will be administered first by IV infusion Q3W on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab at a fixed dose of 1200 mg will be administered first by IV infusion Q3W on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiragolumab
Description: Tiragolumab at a fixed dose of 600 mg will be administered by IV infusion Q3W on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered by IV infusion Q3W on Day 1 of each 21-day cycle.
Study: NCT02535507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib
Description: Drug: Pyrotinib pyrotinib, single agent, 400mg p.o once daily until disease progressed
Study: NCT02627911

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diabeloop System
Description: Insulin delivery

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring

Intervention type: DEVICE
Group type: OTHER
Intervention: Continuous Glucose Monitoring

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accelerometer and heart rate monitor
Description: Monitoring and measurement of physical activity

Intervention type: DEVICE
Group type: OTHER
Intervention: Accelerometer and heart rate monitor
Description: Monitoring and measurement of physical activity

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Meals
Description: Calibrated meals for all patients and outstanding dinners for patients being in outstanding meals situation (Centers : Grenoble, Toulouse, Montpellier)

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Meals
Description: Calibrated meals for all patients and outstanding dinners for patients being in outstanding meals situation (Centers : Grenoble, Toulouse, Montpellier)
Study: NCT03828942

Intervention type: DRUG
Intervention: drug inducing hematological toxicity
Description: Drugs susceptible to induce hematological toxicities
Study: NCT02991625

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebos
Description: Positive treatment expectations will be induced by giving participants capsules containing inert material and telling them that the capsules contain an effective drug that has been approved for treating Chronic Back Pain. They will be requested to take two capsules twice a day and report their pain on paper forms organized as a calendar.

Intervention type: OTHER
Group type: OTHER
Intervention: Waitlist
Description: These Chronic Back Pain participants will not be given any placebos and will be requested to report their pain on paper forms organized as a calendar.

Intervention type: OTHER
Group type: OTHER
Intervention: Healthy Controls
Description: Healthy control participants will not receive a placebo drug or be put on a waitlist.
Study: NCT01106183

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: transfer factor
Description: capsules, 2 per day by mouth for 7 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: cornstarch, 2 capsules per day by mouth.
Study: NCT02559583

Intervention type: OTHER
Intervention: Chronic Lymphocytic Leukemia (CLL)
Description: This is observational study. Participants with Chronic Lymphocytic Leukemia (CLL) will be observed for 1 year.

Intervention type: OTHER
Intervention: Multiple Myeloma (MM)
Description: This is observational study. Participants with Multiple Myeloma (MM) will be observed for 1 year.

Intervention type: OTHER
Intervention: Non-Hodgkin's lymphoma (NHL)
Description: This is observational study. Participants with non-Hodgkin's lymphoma (NHL) will be observed for 1 year.
Study: NCT03203148

Intervention type: DIAGNOSTIC_TEST
Intervention: Point-of-Care ACT
Description: Comparison between two point-of-care devices for measurement of the activated clotting time
Study: NCT03708913

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hypothalamic Deep Brain Stimulation
Description: One-year continuous hypothalamic deep brain stimulation
Study: NCT02707536

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Socket grafting with PRF
Description: Extraction with socket grafting using PRF.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Socket grafting with PRF
Description: Extraction with socket grafting using PRF.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Socket grafting with bone graft
Description: Extraction with socket grafting using bone graft.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Socket grafting with bone graft
Description: Extraction with socket grafting using bone graft.
Study: NCT03958890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX10 100 mg in 10 ml Injection
Description: 3mg/kg IV（HLX10+cis-platinum+5FU）

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: 3mg/kg IV（placebo+cis-platinum+5FU）
Study: NCT02462538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin
Description: Brentuximab vedotin is given in a 21 day cycle intravenously starting at 1.8 mg/kg on day 1 of the first cycle and will be administered by IV infusion given over approximately 30 minutes on day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: Imatinib will be given orally at a dose of 100mg daily starting from day 1 of the first cycle. The dose will be increased to 200mg daily starting from day 1 of the second cycle if no DLT occurs during the first cycle and will be continued at 200mg for 48 weeks.
Study: NCT02426619

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SDF solution
Description: around 1 mL of 30% silver diammine fluoride (SDF) solution is placed in a small disposable container and a small brush will be used to apply a very small quantity of the solution onto the surface of the dental caries lesion in the tooth

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SDF solution
Description: around 1 mL of 30% silver diammine fluoride (SDF) solution is placed in a small disposable container and a small brush will be used to apply a very small quantity of the solution onto the surface of the dental caries lesion in the tooth

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NaF varnish
Description: around 1 mL of 5% NaF (sodium fluoride) varnish is placed in a small disposable container and a small brush will be used to apply a very small quantity of the solution onto the surface of the dental caries lesion in the tooth
Study: NCT03852199

Intervention type: OTHER
Intervention: Test protocol for proprioceptive force sense in case group
Description: * The FS in the knee region was measured by the pressure, biofeedback device (Stabilizer ™, Chattanooga Group Inc., Chattanooga, TN).~* Surface EMG device (Noraxon USA, Inc., Scottsdale, AZ) was used to measure activation levels of M. Vastus Medialis Obliquus (VMO), M. Vastus Lateralis (VL) and M. Rectus Femoris (RF) muscles. Due to the characteristics of the Bipolar Ag/AgCl surface electrodes, the distance between the electrodes was set to 1 cm and the electrode width to 2 cm. The electrode placement was determined according to the SENIAM (Surface ElectroMyoGraphy for the Non-Invasive Assessment of Muscles) criteria.
Study: NCT00648323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxazosin mysylate GITS
Description: Subjects initiated on 4 mg doxazosin GITS once daily at Visit 1 for four weeks. At Visit 2 (Week 4) increased to 8 mg Doxazosin GITS if efficacy response criteria not met.
Study: NCT04534283

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Subjects will receive Abemaciclib 150 mg orally twice daily until disease progression, unacceptable toxicity, or patient preference to withdraw from study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3214996
Description: Subjects will recieve LY3214996 200 mg orally daily until disease progression, unacceptable toxicity, or patient preference to withdraw from study.